Majid Mokhtari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Majid Mokhtari has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Taheri
Institute of Human Genetics, Jena University Hospital, Jena, Germany; Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
13 shared publications Soudeh Ghafouri-Fard
Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
11 shared publicationsBashdar Mahmud Hussen
Department of Clinical Analysis, College of Pharmacy Hawler Medical University Erbil Iraq
10 shared publications- Mohammad Sistanizad
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
9 shared publications - Maryam Farasatinasab
Department of Clinical Pharmacy and Pharmacoeconomics, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
6 shared publications - Mehran Kouchek
Shahid Beheshti Univ Med Sci, Imam Hossein Med & Educ Ctr, Dept Crit Care Med, Tehran, Iran
6 shared publications
Latest Publications
- Open Access
- 31 March 2025
- Published by Brieflands in Journal of Cellular & Molecular Anesthesia
- Vol. 10 (1)
The Impact of Olfactory Dysfunction on Post-operative Cognitive Dysfunction and Delirium: A Systematic Review
Context: Post-operative cognitive dysfunction (POCD) and postoperative delirium (POD) are common complications following major surgery, particularly in older adults. Emerging evidence suggests that olfactory dysfunction may significantly predispose individuals to these cognitive disturbances, potentially serving as an early marker for post-surgical cognitive decline. However, the relationship between olfactory impairment and post-operative cognitive outcomes remains underexplored. Objectives: The present systematic review aims to synthesize current evidence on the impact of olfactory dysfunction on POCD and POD. Evidence Acquisition: The review adhered to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. A comprehensive search of PubMed, Scopus, and the Web of Science (WOS) was conducted from inception until December 2024. Studies on patients undergoing major operations that involved verified olfactory and cognitive examinations and yielded quantitative data were included. Exclusion criteria encompassed research focusing on non-surgical groups, non-original studies, and studies lacking postoperative cognitive assessments. Results: From an initial 389 articles, seven studies met the inclusion criteria, comprising 1,038 participants. These studies, conducted between 2004 and 2022, included patients undergoing major surgeries such as cardiac, abdominal, and neurosurgery. Various olfactory tests [e.g., sniffin’ sticks, brief smell identification test (BSIT)] and cognitive assessments [e.g., mini-mental state examination (MMSE), clock drawing test (CDT)] were used. The findings across studies were heterogeneous but suggested a potential link between olfactory dysfunction and both POCD and POD. Specifically, several studies indicated that impaired olfactory function was associated with an increased risk of delirium (OR = 1.90; 95% CI = 1.17 - 3.09) and cognitive decline post-surgery. Some studies identified olfactory impairment as an independent predictor of worse cognitive outcomes, particularly among frail or elderly populations. Conclusions: The evidence reviewed supports the hypothesis that olfactory dysfunction may be a preoperative marker for POCD, particularly delirium and delayed neurocognitive recovery (dNCR). Based on the obtained results, olfactory testing could be a useful preoperative screening tool, especially in populations at risk for cognitive decline.
- 31 March 2025
- Published by Brieflands in Journal of Cellular & Molecular Anesthesia
- Vol. 10 (1)
Open AccessThe Impact of Olfactory Dysfunction on Post-operative Cognitive Dysfunction and Delirium: A Systematic Review
Context: Post-operative cognitive dysfunction (POCD) and postoperative delirium (POD) are common complications following major surgery, particularly in older adults. Emerging evidence suggests that olfactory dysfunction may significantly predispose individuals to these cognitive disturbances, potentially serving as an early marker for post-surgical cognitive decline. However, the relationship between olfactory impairment and post-operative cognitive outcomes remains underexplored. Objectives: The present systematic review aims to synthesize current evidence on the impact of olfactory dysfunction on POCD and POD. Evidence Acquisition: The review adhered to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. A comprehensive search of PubMed, Scopus, and the Web of Science (WOS) was conducted from inception until December 2024. Studies on patients undergoing major operations that involved verified olfactory and cognitive examinations and yielded quantitative data were included. Exclusion criteria encompassed research focusing on non-surgical groups, non-original studies, and studies lacking postoperative cognitive assessments. Results: From an initial 389 articles, seven studies met the inclusion criteria, comprising 1,038 participants. These studies, conducted between 2004 and 2022, included patients undergoing major surgeries such as cardiac, abdominal, and neurosurgery. Various olfactory tests [e.g., sniffin’ sticks, brief smell identification test (BSIT)] and cognitive assessments [e.g., mini-mental state examination (MMSE), clock drawing test (CDT)] were used. The findings across studies were heterogeneous but suggested a potential link between olfactory dysfunction and both POCD and POD. Specifically, several studies indicated that impaired olfactory function was associated with an increased risk of delirium (OR = 1.90; 95% CI = 1.17 - 3.09) and cognitive decline post-surgery. Some studies identified olfactory impairment as an independent predictor of worse cognitive outcomes, particularly among frail or elderly populations. Conclusions: The evidence reviewed supports the hypothesis that olfactory dysfunction may be a preoperative marker for POCD, particularly delirium and delayed neurocognitive recovery (dNCR). Based on the obtained results, olfactory testing could be a useful preoperative screening tool, especially in populations at risk for cognitive decline.
- Open Access
- 16 November 2024
- Published by Brieflands in Anesthesiology and Pain Medicine
- Vol. 14 (5) , e146811
Enhanced Recovery After Surgery (ERAS) Protocol for Craniotomy Patients: A Systematic Review
Context: The enhanced recovery after surgery (ERAS) protocol is a multidisciplinary approach aimed at improving surgical outcomes, reducing complications, minimizing hospital stays, and lowering healthcare costs. Objectives: This study assesses the impact of the ERAS protocol on elective craniotomies, a routine procedure in neurosurgery. Methods: A comprehensive search across PubMed, Embase, Scopus, and Web of Science identified 562 articles. Following strict screening criteria, 54 studies were reviewed, and ultimately 10 studies meeting the inclusion criteria were selected for detailed analysis. Results: The review encompassed ten studies [one prospective, one systematic review, and eight randomized controlled trials (RCTs)] published between 2016 and 2023. Key components of the ERAS protocol included preoperative counseling, high-protein intestinal nutrition, preoperative fasting while avoiding carbohydrate intake within 2 hours of surgery, standardized anesthetic and analgesic regimens, and early postoperative initiation of enteral feeding. Postoperative outcomes showed fewer complications, early mobilization, and notably shorter hospital stays, all of which contributed to improved patient recovery. Conclusions: This review demonstrates that the ERAS protocol, when applied to elective craniotomies, is effective in enhancing postoperative recovery, improving functional outcomes, and reducing hospitalization duration.
- 16 November 2024
- Published by Brieflands in Anesthesiology and Pain Medicine
- Vol. 14 (5) , e146811
Open AccessEnhanced Recovery After Surgery (ERAS) Protocol for Craniotomy Patients: A Systematic Review
Context: The enhanced recovery after surgery (ERAS) protocol is a multidisciplinary approach aimed at improving surgical outcomes, reducing complications, minimizing hospital stays, and lowering healthcare costs. Objectives: This study assesses the impact of the ERAS protocol on elective craniotomies, a routine procedure in neurosurgery. Methods: A comprehensive search across PubMed, Embase, Scopus, and Web of Science identified 562 articles. Following strict screening criteria, 54 studies were reviewed, and ultimately 10 studies meeting the inclusion criteria were selected for detailed analysis. Results: The review encompassed ten studies [one prospective, one systematic review, and eight randomized controlled trials (RCTs)] published between 2016 and 2023. Key components of the ERAS protocol included preoperative counseling, high-protein intestinal nutrition, preoperative fasting while avoiding carbohydrate intake within 2 hours of surgery, standardized anesthetic and analgesic regimens, and early postoperative initiation of enteral feeding. Postoperative outcomes showed fewer complications, early mobilization, and notably shorter hospital stays, all of which contributed to improved patient recovery. Conclusions: This review demonstrates that the ERAS protocol, when applied to elective craniotomies, is effective in enhancing postoperative recovery, improving functional outcomes, and reducing hospitalization duration.
- Open Access
- 24 July 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (16) , 2278-2289
A concise review on the role of MIR100HG in human disorders
MIR100HG is a long non‐coding RNA (lncRNA) encoded by a locus on chr11:122,028,203‐122,556,721. This gene can regulate cell proliferation, apoptosis, cell cycle transition and cell differentiation. MIR100HG was firstly identified through a transcriptome analysis and found to regulate differentiation of human neural stem cells. It is functionally related with a number of signalling pathways such as TGF‐β, Wnt, Hippo and ERK/MAPK signalling pathways. Dysregulation of MIR100HG has been detected in a diversity of cancers in association with clinical outcomes. Moreover, it has a role in the pathophysiology of dilated cardiomyopathy, intervertebral disk degeneration and pulmonary fibrosis. The current study summarizes the role of these lncRNAs in human disorders.
- 24 July 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (16) , 2278-2289
Open AccessA concise review on the role of MIR100HG in human disorders
MIR100HG is a long non‐coding RNA (lncRNA) encoded by a locus on chr11:122,028,203‐122,556,721. This gene can regulate cell proliferation, apoptosis, cell cycle transition and cell differentiation. MIR100HG was firstly identified through a transcriptome analysis and found to regulate differentiation of human neural stem cells. It is functionally related with a number of signalling pathways such as TGF‐β, Wnt, Hippo and ERK/MAPK signalling pathways. Dysregulation of MIR100HG has been detected in a diversity of cancers in association with clinical outcomes. Moreover, it has a role in the pathophysiology of dilated cardiomyopathy, intervertebral disk degeneration and pulmonary fibrosis. The current study summarizes the role of these lncRNAs in human disorders.
- 24 February 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 244, 154387
Contribution of CRNDE lncRNA in the development of cancer and the underlying mechanisms
- 24 February 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 244, 154387
Contribution of CRNDE lncRNA in the development of cancer and the underlying mechanisms
- 27 January 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 243, 154346
A review on the role of ADAMTS9-AS2 in different disorders
- 27 January 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 243, 154346
A review on the role of ADAMTS9-AS2 in different disorders
- 23 January 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 243, 154339
Deciphering the role of Hippo pathway in lung cancer
- 23 January 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 243, 154339
Deciphering the role of Hippo pathway in lung cancer
- Open Access
- 1 December 2022
- Published by Springer Nature in Cancer Cell International
- Vol. 22 (1) , 1-24
Exosomal circular RNA: a signature for lung cancer progression
Membrane vesicles having a diameter of 30–150 nm are known as exosomes. Several cancer types secrete exosomes, which may contain proteins, circular RNAs (circRNAs), microRNAs, or DNA. CircRNAs are endogenous RNAs that do not code for proteins and can create continuous and covalently closed loops. In cancer pathogenesis, especially metastasis, exosomal circRNAs (exo-circRNAs) have a crucial role mainly due to the frequently aberrant expression levels within tumors. However, neither the activities nor the regulatory mechanisms of exo-circRNAs in advancing lung cancer (LC) are obvious. A better understanding of the regulation and network connections of exo-circRNAs will lead to better treatment for LCs. The main objective of the current review is to highlight the functions and mechanisms of exo-circRNAs in LC and assess the relationships between exo-circRNA dysregulation and LC progression. In addition, underline the possible therapeutic targets based on exo-circRNA modulating.
- 1 December 2022
- Published by Springer Nature in Cancer Cell International
- Vol. 22 (1) , 1-24
Open AccessExosomal circular RNA: a signature for lung cancer progression
Membrane vesicles having a diameter of 30–150 nm are known as exosomes. Several cancer types secrete exosomes, which may contain proteins, circular RNAs (circRNAs), microRNAs, or DNA. CircRNAs are endogenous RNAs that do not code for proteins and can create continuous and covalently closed loops. In cancer pathogenesis, especially metastasis, exosomal circRNAs (exo-circRNAs) have a crucial role mainly due to the frequently aberrant expression levels within tumors. However, neither the activities nor the regulatory mechanisms of exo-circRNAs in advancing lung cancer (LC) are obvious. A better understanding of the regulation and network connections of exo-circRNAs will lead to better treatment for LCs. The main objective of the current review is to highlight the functions and mechanisms of exo-circRNAs in LC and assess the relationships between exo-circRNA dysregulation and LC progression. In addition, underline the possible therapeutic targets based on exo-circRNA modulating.
- Open Access
- 16 November 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 1037149
A long non-coding RNA with important roles in the carcinogenesis
Long non-coding RNAs are demonstrated to contribute to carcinogenesis. TMPO Antisense RNA 1 (TMPO-AS1) is an example of lncRNAs with crucial roles in this process. This lncRNA serves as a sponge for miR-320a, miR-383-5p, miR-329-3p, miR-126, miR-329, miR‐199a‐5p, miR-577, miR-4731-5p, miR-140-5p, miR-1179, miR-143-3p, miR-326, miR-383-5p, let-7c-5p, let-7g-5p, miR-199a-5p, miR-200c, miR-204-3p, miR-126-5p, miR-383-5p, miR-498, miR-143-3p, miR-98-5p, miR-140 and miR-143. It can also affect activity of PI3K/Akt/mTOR pathway. The current review summarizes the role of TMPO-AS1 in the carcinogenesis and assessment of its potential as a marker for certain types of cancers.
- 16 November 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 1037149
Open AccessA long non-coding RNA with important roles in the carcinogenesis
Long non-coding RNAs are demonstrated to contribute to carcinogenesis. TMPO Antisense RNA 1 (TMPO-AS1) is an example of lncRNAs with crucial roles in this process. This lncRNA serves as a sponge for miR-320a, miR-383-5p, miR-329-3p, miR-126, miR-329, miR‐199a‐5p, miR-577, miR-4731-5p, miR-140-5p, miR-1179, miR-143-3p, miR-326, miR-383-5p, let-7c-5p, let-7g-5p, miR-199a-5p, miR-200c, miR-204-3p, miR-126-5p, miR-383-5p, miR-498, miR-143-3p, miR-98-5p, miR-140 and miR-143. It can also affect activity of PI3K/Akt/mTOR pathway. The current review summarizes the role of TMPO-AS1 in the carcinogenesis and assessment of its potential as a marker for certain types of cancers.
- 14 November 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 240, 154223
A review on the role of PCGEM1 lncRNA in cancer
- 14 November 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 240, 154223
A review on the role of PCGEM1 lncRNA in cancer
- Open Access
- 30 August 2022
- Published by Springer Nature in Cancer Cell International
- Vol. 22 (1) , 1-10
A review on the role of LINC01133 in cancers
Long Intergenic Non-Protein Coding RNA 1133 (LINC01133) is a long non-coding RNA (lncRNA) which interacts with miR-106a-3p, miR-576-5p, miR-495-3p, miR-205, miR-199a-5p, miR-4784, miR-30a-5p, miR-199a, miR-30b-5p, miR-216a -5p and miR-422a, thus increasing expression of mRNA targets of these miRNAs. LINC01133 can affect cancer metastasis through regulation of epithelial-mesenchymal transition program. Dysregulation of this lncRNA has been repeatedly detected in the process of tumorigenesis. In this review, we summarize the results of various studies that reported dysregulation of LINC01133 in different samples and described the role of this lncRNA as a marker for these disorders.
- 30 August 2022
- Published by Springer Nature in Cancer Cell International
- Vol. 22 (1) , 1-10
Open AccessA review on the role of LINC01133 in cancers
Long Intergenic Non-Protein Coding RNA 1133 (LINC01133) is a long non-coding RNA (lncRNA) which interacts with miR-106a-3p, miR-576-5p, miR-495-3p, miR-205, miR-199a-5p, miR-4784, miR-30a-5p, miR-199a, miR-30b-5p, miR-216a -5p and miR-422a, thus increasing expression of mRNA targets of these miRNAs. LINC01133 can affect cancer metastasis through regulation of epithelial-mesenchymal transition program. Dysregulation of this lncRNA has been repeatedly detected in the process of tumorigenesis. In this review, we summarize the results of various studies that reported dysregulation of LINC01133 in different samples and described the role of this lncRNA as a marker for these disorders.